Bock Pharmacal/Mimetics to co-develop molecular iodine for benign fibrocystic breast disease.

Executive Summary

BOCK PHARMACAL/MIMETICS TO CO-DEVELOP MOLECULAR IODINE for treatment of fibrocystic breast disease, Bock President William Moskoff announced Jan. 9 at the Hambrecht & Quist Life Sciences Conference in San Francisco. Under the agreement, Bock will receive exclusive marketing rights for the oral formulation in the U.S. and Canada; Mimetics will retain all manufacturing rights. The agreement includes milestone payments, royalties and research funding, Mimetics said. The companies are also in the process of closing an agreement for Bock to take a small equity stake in Mimetics.